Votrient(pazopanib)
Votrient (pazopanib) is a small molecule pharmaceutical. Pazopanib was first approved as Votrient on 2009-10-19. It is used to treat renal cell carcinoma and soft tissue neoplasms in the USA. It has been approved in Europe to treat renal cell carcinoma. The pharmaceutical is active against vascular endothelial growth factor receptor 1, vascular endothelial growth factor receptor 3, and vascular endothelial growth factor receptor 2. In addition, it is known to target fibroblast growth factor receptor 1, mast/stem cell growth factor receptor Kit, macrophage colony-stimulating factor 1 receptor, and platelet-derived growth factor receptor beta.
Download report
Favorite
Novartis Pharmaceuticals
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Votrient
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pazopanib hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VOTRIENT | Novartis | N-022465 RX | 2009-10-19 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| votrient | New Drug Application | 2020-08-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| renal cell carcinoma | EFO_0000376 | D002292 | — |
| soft tissue neoplasms | — | D012983 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Pazopanib Hydrochloride, Votrient, Novartis | |||
| 7105530 | 2023-10-19 | DS, DP | |
HCPCS
No data
Clinical
Clinical Trials
261 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 6 | 12 | 1 | — | — | 15 |
| Non-small-cell lung carcinoma | D002289 | 5 | 9 | 1 | — | — | 14 | ||
| Leiomyosarcoma | D007890 | 2 | 8 | 2 | — | — | 8 | ||
| Osteosarcoma | D012516 | 1 | 4 | 1 | — | — | 5 | ||
| Liposarcoma | D008080 | — | 5 | 1 | — | — | 5 | ||
| Lung neoplasms | D008175 | C34.90 | 1 | 3 | 1 | — | — | 4 | |
| Neurofibrosarcoma | D018319 | 2 | 4 | 1 | — | — | 4 | ||
| Hemangiosarcoma | D006394 | — | 3 | 1 | — | — | 4 | ||
| Alveolar soft part sarcoma | D018234 | — | 3 | 1 | — | — | 3 | ||
| Synovial sarcoma | D013584 | 1 | 3 | 1 | — | — | 3 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 8 | 7 | — | — | — | 15 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 5 | 4 | — | — | — | 9 |
| Prostatic neoplasms | D011471 | C61 | 2 | 4 | — | — | — | 6 | |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | 4 | — | — | — | 6 |
| Melanoma | D008545 | 2 | 4 | — | — | — | 6 | ||
| Glioblastoma | D005909 | EFO_0000515 | 2 | 4 | — | — | — | 5 | |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 2 | 2 | — | — | 1 | 5 |
| Fallopian tube neoplasms | D005185 | 2 | 5 | — | — | — | 5 | ||
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | 3 | — | — | — | 4 |
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | — | 4 | — | — | — | 4 |
Show 50 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | 3 | — | — | — | — | 3 | ||
| Head and neck neoplasms | D006258 | 2 | — | — | — | — | 2 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | — | — | — | — | 2 |
| Syndrome | D013577 | 1 | — | — | — | — | 1 | ||
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | 1 | — | — | — | — | 1 |
| Papillary thyroid cancer | D000077273 | 1 | — | — | — | — | 1 | ||
| Follicular adenocarcinoma | D018263 | 1 | — | — | — | — | 1 | ||
| Neuroblastoma | D009447 | EFO_0000621 | 1 | — | — | — | — | 1 | |
| Wilms tumor | D009396 | 1 | — | — | — | — | 1 | ||
| Colonic neoplasms | D003110 | C18 | 1 | — | — | — | — | 1 |
Show 4 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PAZOPANIB |
| INN | pazopanib |
| Description | Pazopanib is a pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer. It has a role as an antineoplastic agent, a tyrosine kinase inhibitor, a vascular endothelial growth factor receptor antagonist and an angiogenesis modulating agent. It is a member of indazoles, an aminopyrimidine and a sulfonamide. It is a conjugate base of a pazopanib(1+). |
| Classification | Small molecule |
| Drug class | angiogenesis inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O |
Identifiers
| PDB | — |
| CAS-ID | 444731-52-6 |
| RxCUI | 714438 |
| ChEMBL ID | CHEMBL477772 |
| ChEBI ID | 71219 |
| PubChem CID | 10113978 |
| DrugBank | DB06589 |
| UNII ID | 7RN5DR86CK (ChemIDplus, GSRS) |
Target
Agency Approved
FLT1
FLT1
FLT4
FLT4
KDR
KDR
Organism
Homo sapiens
Gene name
FLT1
Gene synonyms
FLT, FRT, VEGFR1
NCBI Gene ID
Protein name
vascular endothelial growth factor receptor 1
Protein synonyms
FLT, FLT-1, fms related tyrosine kinase 1, Fms-like tyrosine kinase 1, fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor), Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, Vascular permeability factor receptor
Uniprot ID
Mouse ortholog
Flt1 (14254)
vascular endothelial growth factor receptor 1 (P35969)
Alternate
FGFR1
FGFR1
KIT
KIT
CSF1R
CSF1R
PDGFRB
PDGFRB
Organism
Homo sapiens
Gene name
FGFR1
Gene synonyms
BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR
NCBI Gene ID
Protein name
fibroblast growth factor receptor 1
Protein synonyms
Basic fibroblast growth factor receptor 1, bFGF-R-1, BFGFR, CD331, FGFR1/PLAG1 fusion, FLT-2, FMS-like tyrosine kinase 2, fms-related tyrosine kinase 2, heparin-binding growth factor receptor, hydroxyaryl-protein kinase, N-sam, Proto-oncogene c-Fgr
Uniprot ID
Mouse ortholog
Fgfr1 (14182)
fibroblast growth factor receptor 1 (P16092)
Variants
Clinical Variant
No data
Financial
Votrient - Novartis
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,695 documents
View more details
Safety
Black-box Warning
Black-box warning for: Votrient
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,240 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more